- Home
- GO vs ALVO Comparison
GO vs ALVO Comparison
Compare GO & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GO | ALVO |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GO | ALVO |
|---|---|---|
| Price | $11.33 | $5.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $11.30 | $8.00 |
| AVG Volume (30 Days) | ★ 2.1M | 956.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,759,000.00 | N/A |
| Revenue This Year | $2.48 | $13.28 |
| Revenue Next Year | $3.91 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.66 | $2.94 |
| 52 Week High | $16.99 | $9.05 |
Technical Indicators
Market Signals| Indicator | GO | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | N/A |
| Support Level | $11.03 | N/A |
| Resistance Level | $12.67 | N/A |
| Average True Range (ATR) | 0.41 | 0.00 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 14.55 | 0.00 |
Price Performance
Historical ComparisonAbout GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.